
    
      The study is Post-Marketing Surveillance on the Long-Term Use of Prazaxa速 Capsules in
      Japanese patients with nonvalvular atrial fibrillation after the availability of
      idarucizumab. Even after the availability of idarucizumab in real clinical practice,
      appropriate use of Prazaxa速 Capsules will continue. The patient population who receive
      Prazaxa速 Capsules and the safety profile of Prazaxa速 Capsules is not expected to change. This
      study can confirm appropriate use with prospective investigation in the routine medical
      practice
    
  